HK1244217A1 - 用於治疗蛋白质病的方法 - Google Patents

用於治疗蛋白质病的方法 Download PDF

Info

Publication number
HK1244217A1
HK1244217A1 HK18103748.9A HK18103748A HK1244217A1 HK 1244217 A1 HK1244217 A1 HK 1244217A1 HK 18103748 A HK18103748 A HK 18103748A HK 1244217 A1 HK1244217 A1 HK 1244217A1
Authority
HK
Hong Kong
Prior art keywords
proteinopathy
subject
methods
quinuclidine compound
administering
Prior art date
Application number
HK18103748.9A
Other languages
English (en)
Chinese (zh)
Inventor
Seng H. Cheng
Lamya Shihabuddin
Sergio Pablo SARDI
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of HK1244217A1 publication Critical patent/HK1244217A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
HK18103748.9A 2015-03-10 2016-03-09 用於治疗蛋白质病的方法 HK1244217A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131071P 2015-03-10 2015-03-10
US62/131,071 2015-03-10
PCT/US2016/021512 WO2016145046A1 (en) 2015-03-10 2016-03-09 Methods for treating proteinopathies

Publications (1)

Publication Number Publication Date
HK1244217A1 true HK1244217A1 (zh) 2018-08-03

Family

ID=55587378

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103748.9A HK1244217A1 (zh) 2015-03-10 2016-03-09 用於治疗蛋白质病的方法

Country Status (17)

Country Link
US (2) US20180036295A1 (enExample)
EP (2) EP3267983B1 (enExample)
JP (2) JP6990110B2 (enExample)
KR (1) KR20170123329A (enExample)
CN (1) CN107872976A (enExample)
AU (1) AU2016229826A1 (enExample)
CA (1) CA2978883A1 (enExample)
EA (1) EA201791993A1 (enExample)
ES (1) ES2973101T3 (enExample)
HK (1) HK1244217A1 (enExample)
HU (1) HUE065628T2 (enExample)
IL (1) IL254393A0 (enExample)
MX (1) MX2017011598A (enExample)
PL (1) PL3267983T3 (enExample)
PT (1) PT3267983T (enExample)
TW (1) TW201642855A (enExample)
WO (1) WO2016145046A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
BR112019027029A2 (pt) * 2017-06-19 2020-07-14 Kainos Medicine, Inc. moduladores de alfa-sinucleina
TWI644673B (zh) * 2017-07-27 2018-12-21 百朗克股份有限公司 頭孢曲松的用途
PL3920912T3 (pl) * 2019-02-04 2025-11-12 Genzyme Corporation Leczenie ciliopatii przy użyciu inhibitorów syntazy glukozyloceramidowej (gcs)
WO2020163245A1 (en) * 2019-02-04 2020-08-13 Genzyme Corporation Methods for treating symptoms and disorders associated with lysosomal storage diseases
WO2021096238A1 (en) * 2019-11-15 2021-05-20 Yuhan Corporation Novel derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
TW202142236A (zh) 2020-02-03 2021-11-16 美商健臻公司 用於治療與溶體儲積症相關的神經症狀之方法
WO2021187486A1 (ja) * 2020-03-17 2021-09-23 大日本住友製薬株式会社 オキサジアゾール誘導体
CA3176609A1 (en) * 2020-03-23 2021-09-30 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
AU2021311131A1 (en) 2020-07-24 2023-03-23 Genzyme Corporation Pharmaceutical compositions comprising venglustat
JP2023535483A (ja) * 2020-07-30 2023-08-17 ジェンザイム・コーポレーション 脳組織中のスフィンゴ糖脂質濃度を低減させるための方法およびそれを含む神経変性疾患の処置方法
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
TW202430159A (zh) 2022-12-01 2024-08-01 美商健臻公司 使用葡萄糖神經醯胺合成酶抑制劑的治療方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US195A (en) 1837-05-15 Machine fob cutting and dressing stone
US4683A (en) 1846-08-08 waring and richard e
BE640616A (enExample) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
LT2685986T (lt) * 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
US9845327B2 (en) * 2011-06-22 2017-12-19 The General Hospital Corporation Treatment of proteinopathies
JOP20130273B1 (ar) * 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد

Also Published As

Publication number Publication date
JP7374149B2 (ja) 2023-11-06
HUE065628T2 (hu) 2024-06-28
JP6990110B2 (ja) 2022-02-10
CA2978883A1 (en) 2016-09-15
CN107872976A (zh) 2018-04-03
JP2018507886A (ja) 2018-03-22
PT3267983T (pt) 2024-03-12
WO2016145046A1 (en) 2016-09-15
TW201642855A (zh) 2016-12-16
EP4349408A3 (en) 2024-06-19
AU2016229826A1 (en) 2017-10-26
EP4349408A2 (en) 2024-04-10
JP2021119185A (ja) 2021-08-12
EP3267983A1 (en) 2018-01-17
EA201791993A1 (ru) 2017-12-29
US20180036295A1 (en) 2018-02-08
PL3267983T3 (pl) 2024-05-13
US20200197374A1 (en) 2020-06-25
ES2973101T3 (es) 2024-06-18
EP3267983B1 (en) 2023-12-20
KR20170123329A (ko) 2017-11-07
MX2017011598A (es) 2017-12-20
IL254393A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
HK1244217A1 (zh) 用於治疗蛋白质病的方法
HK1246286A1 (zh) Lrrk2抑制剂及其制备和使用方法
PT3873604T (pt) Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina
WO2016210372A3 (en) Methods to treat neurological diseases
BR112016011065A8 (pt) composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
BR112016015236A8 (pt) composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença.
EP3140403A4 (en) Prevention and treatment of alzheimer's disease by genome editing using the crispr/cas system
PT3805233T (pt) Enantiómeros (r) e (s) de n-(5-(3-hidroxipirrolidin-1-il)-2 morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)oxazole-carboxamida como inibidores de irak4 para o tratamento de cancro
WO2014160871A3 (en) Methods and agents for treating alzheimer's disease
EP3708168A3 (en) Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation in dementia
HK1252037A1 (zh) 治疗炎性疾病的方法
SG11202011018PA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
HK1210598A1 (en) Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation
EP3773547A4 (en) IDENTIFICATION OF GRANINS AS THE PATHOGENIC FACTOR OF ALZHEIMER'S DISEASE, AND COMPOSITIONS AND METHODS TO INHIBIT GRANIN AGGREGATION AND TREAT ALZHEIMER'S DISEASE
CA3010708A1 (en) Methods of administering hepcidin
SG10202009001TA (en) Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
IL283823A (en) 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
EP3261446A4 (en) Methods and compositions for the treatment or prevention of parkinson's disease
HK1202452A1 (en) Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
MX2016008968A (es) Compuestos organicos.
EP3554496A4 (en) METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE
WO2017103892A3 (en) Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease
EP3634979A4 (en) COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS